FR19C1029I2 - Proteines liant les kallicreines plasmatiques - Google Patents

Proteines liant les kallicreines plasmatiques

Info

Publication number
FR19C1029I2
FR19C1029I2 FR19C1029C FR19C1029C FR19C1029I2 FR 19C1029 I2 FR19C1029 I2 FR 19C1029I2 FR 19C1029 C FR19C1029 C FR 19C1029C FR 19C1029 C FR19C1029 C FR 19C1029C FR 19C1029 I2 FR19C1029 I2 FR 19C1029I2
Authority
FR
France
Prior art keywords
kallicrein
plasmatic
binding proteins
proteins
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR19C1029C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyax Corp
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of FR19C1029I1 publication Critical patent/FR19C1029I1/fr
Application granted granted Critical
Publication of FR19C1029I2 publication Critical patent/FR19C1029I2/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
FR19C1029C 2010-01-06 2019-04-29 Proteines liant les kallicreines plasmatiques Active FR19C1029I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29261410P 2010-01-06 2010-01-06
PCT/US2011/020377 WO2011085103A2 (en) 2010-01-06 2011-01-06 Plasma kallikrein binding proteins

Publications (2)

Publication Number Publication Date
FR19C1029I1 FR19C1029I1 (sr) 2019-06-21
FR19C1029I2 true FR19C1029I2 (fr) 2020-05-15

Family

ID=44306145

Family Applications (1)

Application Number Title Priority Date Filing Date
FR19C1029C Active FR19C1029I2 (fr) 2010-01-06 2019-04-29 Proteines liant les kallicreines plasmatiques

Country Status (21)

Country Link
US (10) US8822653B2 (sr)
EP (3) EP3459564B1 (sr)
JP (6) JP6037841B2 (sr)
AU (1) AU2011204349C1 (sr)
CA (3) CA3021759A1 (sr)
CY (3) CY1122268T1 (sr)
DK (2) DK2521568T3 (sr)
ES (2) ES2905545T3 (sr)
FR (1) FR19C1029I2 (sr)
HR (2) HRP20220107T1 (sr)
HU (3) HUE039605T2 (sr)
LT (3) LT3459564T (sr)
LU (1) LUC00115I2 (sr)
NL (1) NL300986I2 (sr)
NO (1) NO2019020I1 (sr)
PL (2) PL2521568T3 (sr)
PT (2) PT2521568T (sr)
RS (2) RS57870B1 (sr)
SI (2) SI2521568T1 (sr)
SM (2) SMT201800552T1 (sr)
WO (1) WO2011085103A2 (sr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
ES2348230T3 (es) 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
KR102320178B1 (ko) * 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
EP3320922A1 (en) * 2011-06-10 2018-05-16 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
US9322021B2 (en) 2011-06-29 2016-04-26 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
IL230564B2 (en) 2011-07-22 2023-09-01 Csl Ltd Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses.
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
US10690670B2 (en) * 2013-01-20 2020-06-23 Dyax Corp. Assays for determining levels of plasma protease C1 inhibitor
AU2014240045A1 (en) * 2013-03-15 2015-09-10 Dyax Corp. Anti-plasma kallikrein antibodies
CN103336127A (zh) * 2013-05-20 2013-10-02 许瑞安 一种早期肝病、肝纤维化和肝硬化指示剂与诊断剂
KR102365486B1 (ko) 2013-08-28 2022-02-18 아이오니스 파마수티컬즈, 인코포레이티드 프리칼리크레인 (pkk) 발현의 조절
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
CA2927695C (en) 2013-10-21 2022-03-01 Dyax Corp. Diagnosis and treatment of autoimmune diseases
EA038532B1 (ru) * 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
HUE052709T2 (hu) 2014-05-01 2021-05-28 Ionis Pharmaceuticals Inc Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
MY191537A (en) 2014-12-05 2022-06-30 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
SI3226897T1 (sl) 2014-12-05 2021-08-31 Memorial Sloan Kettering Cancer Center Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
CN107405399B (zh) 2015-01-02 2022-02-08 武田药品工业株式会社 针对血浆激肽释放酶和因子xii的双特异性抗体
KR102607829B1 (ko) * 2015-03-30 2023-12-01 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도
AU2016297018B9 (en) 2015-07-21 2022-12-01 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor XIIa
EP4354146B1 (en) 2015-10-19 2026-04-15 Takeda Pharmaceutical Company Limited Immunoassay for the detection of cleaved high molecular weight kininogen
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN108475034B (zh) * 2015-12-25 2021-04-13 佳能株式会社 定影装置和成像装置
WO2017205820A1 (en) * 2016-05-27 2017-11-30 The Board Of Trustees Of The Leland Stanford Junior University Affinity matured broad spectrum antibodies to hepatitis c virus
US11340237B2 (en) 2016-09-16 2022-05-24 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
IL265195B2 (en) 2016-09-16 2025-02-01 Dyax Corp Protein biomarkers for diseases related to the activation system
EA201990730A1 (ru) 2016-09-16 2019-08-30 Дайэкс Корп. Рнк-биомаркеры для наследственного ангионевротического отека
MX2019009552A (es) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
WO2018152452A1 (en) 2017-02-17 2018-08-23 Mapp Biopharmaceutical, Inc. Monoclonal antibodies and cocktails for treatment of ebola infections
EP3612527B1 (en) 2017-04-18 2022-07-20 Takeda Pharmaceutical Company Limited Heterocyclic compounds useful as modulators of acetylcholine receptors
MY201312A (en) 2017-06-02 2024-02-16 Pfizer Antibodies specific for flt3 and their uses
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
MX2020004568A (es) 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
US11957745B2 (en) 2018-02-22 2024-04-16 Vanderbilt University Human Japanese Encephalitis Virus antibodies and methods of use therefor
MA54078A (fr) 2018-11-01 2021-09-15 Juno Therapeutics Inc Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
US12163956B2 (en) 2019-02-21 2024-12-10 Takeda Pharmaceutical Company Limited Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples
WO2020214638A1 (en) 2019-04-16 2020-10-22 Dyax Corp. Methods for quantitation of functional c1 esterase inhibitor (fc1-inh)
CN114423787B (zh) 2019-07-19 2025-01-24 昂科里斯庞斯公司 免疫调节性抗体及其使用方法
EP4076500A4 (en) * 2019-12-19 2023-12-27 Blaze Bioscience, Inc. METHOD FOR TREATING VASCULAR LESIONS AND MALFORMATIONS
EP4090427A1 (en) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
EP4100054A4 (en) * 2020-02-07 2024-07-17 Washington University PROTECTIVE ANTIBODIES AGAINST INFLUENZA B
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
US20230174674A1 (en) * 2020-04-04 2023-06-08 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
KR20230112632A (ko) * 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
EP4262871A4 (en) * 2020-12-18 2025-04-02 Bioardis LLC FAP-BINDING MOLECULES AND THEIR USES
CN114790245A (zh) * 2021-01-25 2022-07-26 成都康弘生物科技有限公司 一种抗体及其用途
WO2022165130A1 (en) * 2021-01-28 2022-08-04 Astria Therapeutics, Inc. Plasma kallikrein antibodies and uses thereof
IL308609A (en) 2021-05-19 2024-01-01 Asher Biotherapeutics Inc IL-21 polypeptides and target constructs
US12042509B2 (en) 2021-10-01 2024-07-23 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
US12487299B2 (en) 2022-06-20 2025-12-02 Shanghai United Imaging Healthcare Co., Ltd. Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices
EP4548103A2 (en) 2022-06-30 2025-05-07 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment
WO2024206568A2 (en) * 2023-03-31 2024-10-03 Ibio, Inc. Anti-cd3 antibodies

Family Cites Families (251)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6915369D0 (pt) * 1969-02-27 1973-03-13 Bayer Ag Emprego de inibidores biologicos de proteases para conservacao de orgaos tecidos e alimentos
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2619246A1 (de) * 1976-04-30 1977-11-10 Bayer Ag Desamino-derivate des kallikrein- trypsin-inhibitors, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
DE2654124A1 (de) * 1976-11-29 1978-06-01 Bayer Ag Derivate des trypsin-kallikrein-inhibitors aus rinderorganen (bpti) mit proteasenhemmwirkung und antiphlogistischer wirkung, ihre herstellung und ihre verwendung als arzneimittel
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
AT359653B (de) * 1979-02-15 1980-11-25 Immuno Ag Verfahren zur herstellung eines gewebekleb- stoffes
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
US4657893A (en) * 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US4609725A (en) * 1984-10-09 1986-09-02 Merck & Co., Inc. Cardiac atrial peptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
CA1312564C (en) * 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
JPH0623113B2 (ja) 1986-01-31 1994-03-30 浩 前田 癌性胸・腹水貯留抑制剤
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
EP0296171A4 (en) * 1986-03-03 1989-11-07 Brigham & Womens Hospital ASSESSMENT PROCEDURE FOR NEPHROTOXICITY.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0255011A3 (en) 1986-07-29 1988-11-23 Miles Inc. Human inter-alpha-trypsin inhibitor gene
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0332640A1 (en) 1986-11-17 1989-09-20 California Biotechnology, Inc. Recombinant alzheimer's amyloid protein
EP0285123A3 (en) 1987-04-03 1989-02-01 Stabra AG A method for complete mutagenesis of nucleic acids
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87172A (en) 1987-07-23 1994-12-29 Univ Washington Method of isolating highly purified tissue factor inhibitor
GB2208511A (en) 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK225488D0 (da) 1988-04-26 1988-04-26 Novo Industri As Polypeptid
ATE81724T1 (de) 1987-11-09 1992-11-15 Becton Dickinson Co Verfahren zur analyse haematopoietischer zellen in einer probe.
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US7078383B2 (en) 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
US5045452A (en) * 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5372933A (en) * 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0401508T3 (da) 1989-05-13 1995-05-15 Bayer Ag Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
US5278285A (en) * 1990-02-01 1994-01-11 Bayer Aktiengesellschaft Variant of Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5278144A (en) * 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
IL99585A0 (en) 1990-10-01 1992-08-18 Novo Nordisk As Aprotinin analogues,their production and pharmaceutical compositions containing them
CA2055425A1 (en) 1990-11-13 1992-05-14 Hideaki Morishita Polypeptide, dna fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5304122A (en) 1991-02-14 1994-04-19 Medtronic, Inc. Method for providing a restenosis model in porcine coronary arteries
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
US20030223977A1 (en) 1991-03-01 2003-12-04 Ley Arthur Charles Kunitz domain mutants as cathepsin G inhibitors
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
US5166133A (en) * 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993009233A2 (en) 1991-10-31 1993-05-13 The Salk Institute Biotechnology/Industrial Associates Inc. Recombinant amyloid precursor protein inhibitor domain and treatment of various disease states
IL104325A (en) * 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104324A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104314A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
IL104327A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
JPH07509229A (ja) * 1992-07-13 1995-10-12 コルバス・インターナショナル、インコーポレイテッド ウシ膵トリプシン阻害因子から誘導される因子Xaの阻害因子
WO1994012637A2 (en) * 1992-12-02 1994-06-09 Zymogenetics, Inc. Novel human amyloid protein precursor homologue and kunitz-type inhibitors
US5436153A (en) * 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
US5426224A (en) * 1993-03-18 1995-06-20 The University Of North Carolina At Chapel Hill Mammalian DNA topoisomerase II inhibitor and method
CA2170030A1 (en) * 1993-09-14 1995-03-23 Robert A. Lazarus Pharmaceutical compositions containing ecotin and homologs thereof
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ATE277081T1 (de) 1994-01-11 2004-10-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
WO1995021601A2 (en) 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
NZ284766A (en) * 1994-06-02 1998-06-26 Merrell Pharma Inc Perfluoro amino ketones; medicaments as elastase inhibitors
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
DE69528591T2 (de) * 1994-08-05 2003-02-20 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Herstellung des inhibitors fuer die komplexbildung des gewebefaktors
US5648331A (en) * 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
EP0788546B9 (en) * 1994-10-18 2007-06-13 Dendreon Corporation Nematode-extracted serine protease inhibitors and anticoagulant proteins
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
WO1996019233A2 (en) * 1994-12-12 1996-06-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ,インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
DE69630214T2 (de) 1995-03-10 2004-07-15 Berlex Laboratories, Inc., Richmond Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5804376A (en) * 1995-05-02 1998-09-08 Incyte Pharmaceuticals, Inc. Pancreas-derived serpin
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
KR19990008458A (ko) 1995-05-08 1999-01-25 쉬어러 피터 알. 쿠니츠(kunitz) 타입 프로테아제 억제 물질
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US6126933A (en) 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JPH0959838A (ja) 1995-08-24 1997-03-04 Kuraray Co Ltd 紡績糸
CN1200036A (zh) * 1995-09-14 1998-11-25 Lxr生物技术有限公司 含有磷脂混合物并具有抗细胞程序死亡活性的组合物
CA2232834A1 (en) * 1995-09-21 1997-03-27 University Of Utah Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
JP3469584B2 (ja) 1996-03-11 2003-11-25 バイエル コーポレイション ヒト ビクニン
US6013763A (en) * 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A
US5869637A (en) * 1996-07-22 1999-02-09 Incyte Pharmaceuticals, Inc. Human Kallikrein
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
ATE332368T1 (de) 1997-01-21 2006-07-15 Gen Hospital Corp Selektion von proteinen mittels rns-protein fusionen
US5840871A (en) * 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
JP2001504709A (ja) 1997-01-31 2001-04-10 ヒューマン ジノーム サイエンシーズ,インコーポレイテッド 組織因子経路インヒビター3
US5962300A (en) 1997-03-26 1999-10-05 Incyte Pharmaceuticals, Inc. Human kallikrein
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
PT1053019E (pt) 1998-01-07 2004-04-30 Debio Rech Pharma Sa Acrilatos de poli(etileno-glicol) heterobifuncional degradaveis e geles e conjugados derivados dos mesmos
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル,コーポレイション 近位の反応性基を持つポリ(エチレングリコール)誘導体
DE69929311T2 (de) 1998-03-24 2006-09-07 Nof Corp. Oximanderivate und verfahren zu ihrer herstellung
US6017723A (en) * 1998-03-27 2000-01-25 Long Island Jewish Medical Center Method for isolating inhibitors of protease activity
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6001596A (en) * 1998-05-07 1999-12-14 Incyte Pharmaceuticals, Inc. Growth-associated protease inhibitor heavy chain precursor
US6087473A (en) * 1999-05-26 2000-07-11 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
JP2002517197A (ja) 1998-06-03 2002-06-18 サイオス,インコーポレーテッド プロテアーゼインヒビターペプチド
US6034053A (en) 1998-07-13 2000-03-07 Wayne Hughes Institute EGF-isoflavone conjugates for the prevention of restenosis
ATE498409T1 (de) 1998-08-06 2011-03-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CA2342072C (en) 1998-09-03 2005-01-11 Zymogenetics, Inc. Kunitz domain polypeptide zkun6
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6114382A (en) 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
EP1135493A2 (en) 1998-11-30 2001-09-26 Eli Lilly And Company Erythropoietic compounds
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6610503B1 (en) 1999-03-17 2003-08-26 Xenogen Corporation Animal models for predicting sepsis mortality
US20030012969A1 (en) 1999-04-06 2003-01-16 Clark Bert Thomas Soluble membrane strengthened paper products
US6605316B1 (en) 1999-07-31 2003-08-12 The Regents Of The University Of California Structures and fabrication techniques for solid state electrochemical devices
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
CA2390292A1 (en) 1999-11-12 2001-05-25 Maxygen Holdings Ltd. Interferon gamma conjugates
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6544760B2 (en) 1999-12-22 2003-04-08 Zymogenetics, Inc. Kunitz domain polypeptide Zkun11
MXPA02006215A (es) 1999-12-22 2003-10-15 Nektar Therapeutics Al Corp Metodo para preparar esteres de 1-benzotriazolil carbonato de poli(etilenglicol).
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20020102703A1 (en) 1999-12-29 2002-08-01 Sheppard Paul O. Kunitz domain polypeptide zkun10
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
WO2001068707A1 (en) 2000-03-13 2001-09-20 Eli Lilly And Company Human hepatocyte growth factor activator inhibitor homologue
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
CN1331213A (zh) 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人大蛋白10.01和编码这种多肽的多核苷酸
DE10034357C1 (de) 2000-07-14 2001-12-13 Elotherm Gmbh Verfahren und Vorrichtung zum Härten von Flächen an Bauteilen
CN100396329C (zh) 2000-10-31 2008-06-25 德比奥药物股份有限公司 Epi-hne蛋白质悬浮液,其制备方法,其派生的干粉气溶胶,含有所述悬浮液或气溶胶的药物组合物及其应用
WO2002061131A2 (en) 2000-12-04 2002-08-08 Bristol-Myers Squibb Company Human single nucleotide polymorphisms
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
JP2004531550A (ja) 2001-05-11 2004-10-14 アラダイム コーポレーション 吸入によって送達されるタンパク質の、分子性状の最適化方法および製剤
CZ20033182A3 (cs) 2001-05-21 2004-09-15 Nektar Therapeutics Inzulínový prostředek a způsob podávání inzulínu
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US20030096733A1 (en) 2001-07-10 2003-05-22 Omnio Ab Novel drug targets for arthritis
JP4287269B2 (ja) 2001-07-10 2009-07-01 日本電産サンキョー株式会社 バルブ駆動装置
US6913900B2 (en) * 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
DK2093286T3 (da) 2001-10-01 2013-05-13 Dyax Corp Flerkædede, eukaryote displayvektorer og anvendelser deraf
US20040005709A1 (en) 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
JP4653915B2 (ja) 2001-10-29 2011-03-16 独立行政法人科学技術振興機構 全身性エリテマトーデスモデル非ヒト動物
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
WO2003066824A2 (en) 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ES2348230T3 (es) 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
MXPA05000796A (es) 2002-07-24 2005-04-19 Hoffmann La Roche Aditivos de acidos polialquilenglicolicos.
HRP20050024A2 (en) 2002-07-24 2006-02-28 F. Hoffmann - La Roche Ag Pegylated t20 polypeptide
EP2386310B1 (en) 2002-08-28 2018-11-07 Dyax Corp. Methods for preserving organs and tissues
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
JP5207590B2 (ja) 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ,インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
DK1587907T3 (da) 2003-01-07 2011-04-04 Dyax Corp Kunitz-domænebibliotek
DE602004019761D1 (de) 2003-01-08 2009-04-16 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
CA2512680A1 (en) 2003-01-08 2004-07-29 Chiron Corporation Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
GB0303085D0 (en) 2003-02-11 2003-03-19 Pfizer Ltd Model
JP2007528721A (ja) 2003-08-14 2007-10-18 ダイアックス コーポレイション エンドセリアーゼ−2リガンド
AU2004268144A1 (en) 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
US20050089515A1 (en) 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
US7803553B2 (en) * 2003-09-04 2010-09-28 Riken Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-β
WO2005027753A1 (en) 2003-09-19 2005-03-31 St. Jude Medical, Inc. Apparatus and methods for tissue gathering and securing
CA2540895C (en) 2003-10-02 2016-08-02 Elan Pharmaceuticals, Inc. Combinations of ziconotide and opioids for reducing pain
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
US20050164945A1 (en) 2003-10-21 2005-07-28 Andrew Nixon Endotheliase-1 ligands
US20070253949A1 (en) 2004-02-03 2007-11-01 Stefan Golz Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1)
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1835926A4 (en) 2004-11-22 2009-04-01 Dyax Corp PLASMINE-INHIBITING THERAPIES
CA2591786C (en) 2004-12-23 2013-07-16 Bernhard Nieswandt Prevention of thrombus formation and/or stabilization
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
UA95235C2 (en) 2005-05-04 2011-07-25 Зииланд Фарма А/С Glucagon-like-peptide-2 (glp-2) analogues
US20070079096A1 (en) 2005-09-30 2007-04-05 Chih-Wei Chen Data storage unit access authorization table automatic rebuilding method and system
PL1981519T3 (pl) 2005-12-29 2018-07-31 Dyax Corp. Hamowanie proteaz
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
EP2001500A4 (en) 2006-03-10 2010-07-28 Dyax Corp FORMULATIONS FOR ECALLANTIDE
WO2007104541A2 (en) 2006-03-16 2007-09-20 Dyax Corp. Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
EP1873344A1 (de) 2006-06-30 2008-01-02 Sika Technology AG Mittels Silikon agedichtete Verklebung
WO2008016883A2 (en) 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
WO2008060764A2 (en) 2006-10-05 2008-05-22 Drugtech Corporation Topical therapies for oral mucositis and other conditions
KR100846354B1 (ko) 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
US20090075887A1 (en) 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
WO2009026539A1 (en) 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
US20090215119A1 (en) 2008-02-13 2009-08-27 Dyax Corp. Methods for producing specific binding pairs
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
DE102008033095A1 (de) 2008-07-15 2010-01-28 Uhde Gmbh Vorrichtung zur Schlackeabführung aus einem Kohlevergasungsreaktor
MX2011000071A (es) 2008-07-02 2011-05-03 Emergent Product Dev Seattle Inmunoterapeuticos de interleucina-6 (il6).
US8637454B2 (en) * 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CN101928346B (zh) 2009-07-31 2013-01-16 华中科技大学同济医学院附属同济医院 一种抗人组织激肽释放酶单克隆抗体及其制备
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
MX367097B (es) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
JP6345123B2 (ja) 2012-02-16 2018-06-20 サンタラス, インコーポレイテッド 抗vla1(cd49a)抗体医薬組成物
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
US10690670B2 (en) 2013-01-20 2020-06-23 Dyax Corp. Assays for determining levels of plasma protease C1 inhibitor
AU2014240045A1 (en) 2013-03-15 2015-09-10 Dyax Corp. Anti-plasma kallikrein antibodies
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
KR102607829B1 (ko) 2015-03-30 2023-12-01 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US11340237B2 (en) 2016-09-16 2022-05-24 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
EP3678553B1 (en) 2017-09-05 2024-05-22 Sanolla Ltd Diagnosis of pathologies using infrasonic signatures
CN113056304A (zh) 2018-08-30 2021-06-29 戴埃克斯有限公司 用于治疗遗传性血管性水肿发作的血浆激肽释放酶抑制剂及其用途
AU2020237259A1 (en) 2019-03-14 2021-10-14 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP4090427A1 (en) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Also Published As

Publication number Publication date
US20140335023A1 (en) 2014-11-13
JP6779944B2 (ja) 2020-11-04
CA3021759A1 (en) 2011-07-14
EP2521568B1 (en) 2018-07-25
LT3459564T (lt) 2022-03-10
SI3459564T1 (sl) 2022-06-30
JP2017081919A (ja) 2017-05-18
RS57870B1 (sr) 2018-12-31
SMT202200056T1 (it) 2022-03-21
JP7146871B2 (ja) 2022-10-04
DK2521568T3 (en) 2018-11-19
EP4011917A1 (en) 2022-06-15
ES2688093T3 (es) 2018-10-30
US20180037665A1 (en) 2018-02-08
PT3459564T (pt) 2022-01-31
NL300986I2 (nl) 2019-11-21
US20200109213A1 (en) 2020-04-09
HUS1900023I1 (hu) 2019-04-23
AU2011204349B2 (en) 2014-09-04
CY1125705T1 (el) 2024-02-16
AU2011204349C1 (en) 2017-02-16
US10336832B2 (en) 2019-07-02
JP2021006582A (ja) 2021-01-21
RS62853B1 (sr) 2022-02-28
HUE057244T2 (hu) 2022-04-28
ES2905545T3 (es) 2022-04-11
FR19C1029I1 (sr) 2019-06-21
EP3459564B1 (en) 2021-10-27
PL3459564T3 (pl) 2022-04-19
WO2011085103A2 (en) 2011-07-14
HUE039605T2 (hu) 2019-01-28
PT2521568T (pt) 2018-10-26
HRP20181419T1 (hr) 2018-11-16
US12460016B2 (en) 2025-11-04
NL300986I1 (nl) 2019-05-15
JP2013516478A (ja) 2013-05-13
WO2011085103A3 (en) 2011-09-09
CA2786019A1 (en) 2011-07-14
US20180002448A1 (en) 2018-01-04
HRP20220107T1 (hr) 2022-04-15
JP6356199B2 (ja) 2018-07-11
JP2022188112A (ja) 2022-12-20
JP2025029090A (ja) 2025-03-05
EP2521568A2 (en) 2012-11-14
EP2521568A4 (en) 2013-06-12
CA3168591A1 (en) 2011-07-14
CY2019020I2 (el) 2020-05-29
US20180002447A1 (en) 2018-01-04
LTC2521568I2 (lt) 2020-05-11
US8822653B2 (en) 2014-09-02
SMT201800552T1 (it) 2018-11-09
JP2018197234A (ja) 2018-12-13
US20180037664A1 (en) 2018-02-08
JP6037841B2 (ja) 2016-12-07
LUC00115I2 (sr) 2024-05-22
AU2011204349A1 (en) 2012-08-02
CA2786019C (en) 2018-12-18
DK3459564T3 (da) 2022-02-07
EP3459564A1 (en) 2019-03-27
US11505620B2 (en) 2022-11-22
US20180002449A1 (en) 2018-01-04
NO2019020I1 (no) 2019-04-25
US20180037666A1 (en) 2018-02-08
LTPA2019012I1 (lt) 2019-05-27
US20230340150A1 (en) 2023-10-26
PL2521568T3 (pl) 2019-03-29
CY2019020I1 (el) 2020-05-29
CY1122268T1 (el) 2020-05-29
US20110200611A1 (en) 2011-08-18
LT2521568T (lt) 2018-12-10
SI2521568T1 (sl) 2019-01-31

Similar Documents

Publication Publication Date Title
FR19C1029I2 (fr) Proteines liant les kallicreines plasmatiques
HRP20150241T1 (xx) Antikancerogeni fuzijski protein
CR20130266A (es) PROTEÍNAS DE UNIÓN AL TNF-a
HUE036081T2 (hu) Mirac proteinek
EP2728002A4 (en) HETERODIMIZED POLYPEPTIDE
EP2929045A4 (en) PROTEIN EXPRESSION REINFORCING POLYPEPTIDES
BR112013017629A2 (pt) laminina-521 recombinante
EP2940135A4 (en) HETERODIMIZED POLYPEPTIDE
EP2753635A4 (en) P53-ACTIVATING PEPTIDES
DK2536830T3 (da) Polypeptider
EP2714084A4 (en) FC RECEPTOR BINDING PROTEINS
EP2661450A4 (en) PLASMA KALLIKER BINDING PROTEINS
CO7020851A2 (es) Proteínas y péptidos modificados
IL225897B (en) Cxcr2 binding polypeptides
EP2545080A4 (en) NPP1 FUSION PROTEIN
DK2598514T3 (da) Proteinoprensning
ME02224B (me) Antikancerski fuzioni protein
EP2566333A4 (en) IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
BR112013008347A2 (pt) polipeptídeos de variantes cbh i
EP2949750A4 (en) ANTIBODY-BINDING PEPTIDE
FI20116212L (fi) Polypeptidi
EP2698386A4 (en) FUSION PROTEIN
IL225495B (en) Antimicrobial protein
BR112014028441A2 (pt) composição de proteína
BR112013009679A2 (pt) peptídeo